Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-18. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Expanded PBM coverage for oral obesity drug Foundayo defends metabolic franchise cash flows against competing injectable GLP-1 therapies.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factMounjaro and Zepbound generated $27.7 billion in first-half 2026 sales. |
| What else was confirmed? | Reported factOral obesity treatment Foundayo secured coverage across major pharmacy benefit managers. |
| Does the valuation support acting? | Interpretation5 stored valuation assumptions for LLY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownWeekly Foundayo prescription dispense counts — IQVIA prescription trends for newly covered oral obesity therapies. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales.
- · Oral obesity treatment Foundayo secured coverage across major pharmacy benefit managers.
- · Non-GLP-1 therapies grew 121% year-over-year in Q2 2026.
- · Eli Lilly shares fell approximately 7% over the past month.
Public research record
Research framework · page evidenceCompleted event assessment
prescription volume growth via expanded commercial PBM formulary coverage
| Type | Claim | Scope |
|---|---|---|
| Assumption | Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales. | 2026-09-18 |
| Interpretation | prescription volume growth via expanded commercial PBM formulary coverage | LLY |
Countercase, invalidators, and sources
Rapid commercial prescription uptake for oral Foundayo offsets pricing concessions, driving FY2026 revenue above guidance.
- · Weekly Foundayo prescription dispense counts — IQVIA prescription trends for newly covered oral obesity therapies.
- LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious? · 2026-09-17
What remains unresolved
- Base path
- PBM formulary rollout proceeds steadily, stabilizing LLY market share in the obesity class.
- Adverse path
- Manufacturing bottlenecks or reimbursement hurdles limit oral pill fulfillment, slowing franchise acceleration.
- Supportive path
- Rapid commercial prescription uptake for oral Foundayo offsets pricing concessions, driving FY2026 revenue above guidance.
- · Weekly Foundayo prescription dispense counts — IQVIA prescription trends for newly covered oral obesity therapies.this week
Evidence
- LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?2026-09-17
“Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in first-half 2026 sales and continues driving growth. The company's oral obesity pill Foundayo shows encouraging uptake with coverage across major PBMs, while newer therapies grew 121% in Q2.”
Supports: Eli Lilly GLP-1 portfolio generated $27.7B in 1H 2026; Foundayo gained major PBM coverage.